Skip to content

Dianthus 制药

US · DNTH #2155 按市值排名 上市于 1970
72.09 -2.44 -3.27%
实时 - 追踪5344个代码 - 心跳于471秒前 · 2026-10-16 20:01

✦ 量化股权信号 计算方式说明

减持
  • 最近一期（2026/Q3）披露持股的机构数量增加了2家。
  • 机构持股总比例下降了2.2个百分点。

机构持股

机构持股比例
124.60% -2.21pp
机构数量
330 +2
数据截至
2026/Q3 较上一报告期

持股变动 vs 资金流向

方向分歧

机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流入——两者方向出现分歧。

机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。

持股人类型

Mutual Fund80.61%
Hedge Fund29.82%
VC/PE Fund10.46%
Public Company1.30%
Private Company0.99%
Sovereign Wealth Fund0.75%
Government Pension Fund0.36%
Insurance Company0.31%
Individual/Insider0.15%

主要股东 截至 2026-06-30

FMR 14.66% · 8.20M 股
T. Rowe Price Group, Inc. 11.86% · 6.63M 股
BlackRock 7.37% · 4.12M 股
Wellington Management Group 5.77% · 3.23M 股
Fairmount Funds Management LLC 4.54% · 2.54M 股
Vanguard Capital Management, LLC 4.40% · 2.46M 股
State Street Global Advisors 4.21% · 2.36M 股
Avidity Partners Management, L.P. 3.76% · 2.10M 股
Octagon Capital Advisors LP 3.29% · 1.84M 股
TCG Crossover Management, LLC 3.00% · 1.68M 股

条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。

内部人持股

共追踪50份申报 · 28次买入 · 22次卖出

姓名职务持股比例
Marino Garcia Chief Executive Officer 0.12%
Adam Veness General Counsel 0.03%
Simrat Randhawa Chief Medical Officer 0.01%
Alison Lawton Director --
Sujay Kango Director --
Anne McGeorge Director --
Edward Carr Chief Accounting Officer --
Jonathan Violin Director --
Steven Romano Director --
Paula Soteropoulos Director --

内部人交易 最近的 Form 4 申报记录

日期姓名职务类型股数价格
2026-09-16 Edward Carr Chief Accounting Officer Derivative Exercise and Sale -20,000 $17.88–104.39
2026-08-31 Simrat Randhawa Chief Medical Officer Derivative Exercise and Sale -23,124 $17.88–106.74
2026-08-18 Simon Read Independent Director Derivative Exercise and Sale -2,778 $18.36–117.55
2026-08-12 Adam Veness General Counsel Derivative Exercise and Retained +15,000 $18.17
2026-08-09 Anne McGeorge Director Derivative Exercise and Sale -7,750 $11.20–111.41
2026-08-09 Simon Read Independent Director Derivative Exercise and Sale -2,777 $18.36–111.77
2026-08-09 Adam Veness General Counsel Derivative Exercise and Sale -20,000 $17.88–111.18
2026-08-06 Marino Garcia Chief Executive Officer Derivative Exercise and Sale -166,000 $8.44–110.76
2026-07-08 Ryan Savitz Chief Financial Officer Derivative Exercise and Sale -31,249 $21.77–101.97
2026-06-16 Adam Veness General Counsel Derivative Exercise and Sale -30,000 $17.88–81.38
2026-05-31 Simrat Randhawa Chief Medical Officer Derivative Exercise and Sale -26,530 $8.44–91.37
2026-05-20 Alison Lawton Director Other Derivative Acquisition +6,090 $89.63
2026-05-20 Sujay Kango Director Other Derivative Acquisition +6,090 $89.63
2026-05-20 Anne McGeorge Director Other Derivative Acquisition +6,090 $89.63
2026-05-20 Jonathan Violin Director Other Derivative Acquisition +6,090 $89.63
2026-05-20 Steven Romano Director Other Derivative Acquisition +6,090 $89.63
2026-05-20 Paula Soteropoulos Director Other Derivative Acquisition +6,090 $89.63
2026-05-20 Simon Read Independent Director Other Derivative Acquisition +6,090 $89.63
2026-05-07 Paula Soteropoulos Director Derivative Exercise and Sale -599 $8.44–85.47
2026-04-08 Ryan Savitz Chief Financial Officer Derivative Exercise and Sale -8,224 $17.88–89.84

Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。

报价时间 2026-10-16 20:01:06 · 仅供参考，不构成投资建议，也未考虑您的具体情况。

Dianthus 制药 讨论区 0 条评论

发表评论